1 A high-resolution HLA reference panel capturing global population diversity

2 enables multi-ethnic fine-mapping in HIV host response

- ³ Yang Luo^{1,2,3,4,5}, Masahiro Kanai^{5,4,6,7,8}, Wanson Choi⁹, Xinyi Li¹⁰, Kenichi Yamamoto^{8,11}, Kotaro
- ⁴ Ogawa^{8,12}, Maria Gutierrez-Arcelus^{1,2,3,4,5}, Peter K. Gregersen¹³, Philip E. Stuart¹⁴, James T.
- ⁵ Elder^{14,15}, Jacques Fellay^{16,17}, Mary Carrington^{18,19}, David W. Haas^{20,21}, Xiuqing Guo²², Nicholette
- 6 D. Palmer²³, Yii-Der Ida Chen²², Jerome. I. Rotter²², Kent. D. Taylor²², Stephen. S. Rich²⁴, Adolfo
- ⁷ Correa²⁵, James G. Wilson²⁶, Sekar Kathiresan^{5,27,28}, Michael H. Cho²⁹, Andres Metspalu³⁰, Tonu
- 8 Esko^{5,30}, Yukinori Okada^{8,31}, Buhm Han³², NHLBI Trans-Omics for Precision Medicine (TOPMed)
- ⁹ Consortium, Paul J. McLaren^{33,34}, Soumya Raychaudhuri^{1,2,3,4,5,35}
- 10 1 Center for Data Sciences, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
- 11 2 Division of Rheumatology, Immunology, and Immunity, Brigham and Women's Hospital, Harvard
- 12 Medical School, Boston, MA, USA
- 13 3 Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
- 14 4 Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA
- 15 5 Broad Institute of MIT and Harvard, Cambridge, MA, USA
- 16 6 Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA
- 17 7 Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA, USA
- 18 8 Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, 565-0871,
- 19 Janar
- 20 9 Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, South Korea
- 21 10 Committee on Genetics, Genomics, and Systems Biology, University of Chicago, Chicago, IL, USA
- 22 11 Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
- 23 12 Department of Neurology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
- 24 13 The Robert S. Boas Center for Genomics and Human Genetics, Feinstein Institute for Medical
- 25 Research, North Short LIJ Health System, Manhasset, NY, USA
- 26 14 Department of Dermatology, University of Michigan, Ann Arbor, Michigan, USA
- 27 15 Ann Arbor Veterans Affairs Hospital, Ann Arbor, Michigan, USA
- 28 16 Precision Medicine Unit, Lausanne University Hospital and University of Lausanne, Lausanne,
- 29 Switzerland
- 30 17 School of Life Sciences, EPFL, Lausanne, Switzerland
- 31 18 Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland,
- 32 USA
- 33 19 Ragon Institute of MGH, MIT and Harvard, Boston, Massachusetts, USA
- 34 20 Vanderbilt University Medical Center, Nashville, TN, USA
- 35 21 Meharry Medical College, Nashville, TN, USA
- 36 22 The Institute for Translational Genomics and Population Sciences, Department of Pediatrics, The
- 37 Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA USA
- 38 23 Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
- 39 24 Center for Public Health Genomics, University of Virginia School of Medicine Charlottesville, VA, USA

- 40 25 Medicine, University of Mississippi Medical Center, MS, USA
- 41 26 Physiology and Biophysics, University of Mississippi Medical Center, MS, USA
- 42 27 Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- 43 28 Cardiology Division of the Department of Medicine, Massachusetts General Hospital, Boston, MA,
- 44 USA
- 45 29 Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital,
- 46 Harvard Medical School, Boston, MA, USA
- 47 30 Estonian Genome Center, Institute of Genomics, University of Tartu, Estonia
- 48 31 Laboratory of Statistical Immunology, Immunology Frontier Research Center (WPI-IFReC), Osaka
- 49 University, Suita 565-0871, Japan
- 50 32 Department of Medicine, Seoul National University College of Medicine, Seoul, Korea
- 51 33 J.C. Wilt Infectious Diseases Research Centre, National Microbiology Laboratories, Public Health
- 52 Agency of Canada, Winnipeg, Canada
- 53 34 Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg,
- 54 Canada
- 55 35 Centre for Genetics and Genomics Versus Arthritis, University of Manchester, Manchester, UK

56 Correspondence to

- 57 Yang Luo
- 58 Harvard New Research Building
- 59 77 Avenue Louis Pasteur, Suite 255
- 60 Boston, MA 02115
- 61 yangluo@broadinstitute.org
- 62 Tel: 617-525-4468
- 63 Soumya Raychaudhuri
- 64 Harvard New Research Building
- 65 77 Avenue Louis Pasteur, Suite 250
- 66 Boston, MA 02115
- 67 soumya@broadinstitute.org
- 68 Tel: 617-525-4484 Fax: 617-525-4488

69 Abstract

Defining causal variation by fine-mapping can be more effective in multi-ethnic genetic studies, particularly in regions such as the MHC with highly population-specific 71 structure. To enable such studies, we constructed a large (N=21,546) high resolution HLA reference panel spanning five global populations based on whole-genome sequencing 73 data. Expectedly, we observed unique long-range HLA haplotypes within each population group. Despite this, we demonstrated consistently accurate imputation at G-group 75 resolution (94.2%, 93.7%, 97.8% and 93.7% in Admixed African (AA), East Asian (EAS), 76 European (EUR) and Latino (LAT)). We jointly analyzed genome-wide association studies 77 (GWAS) of HIV-1 viral load from EUR, AA and LAT populations. Our analysis pinpointed the MHC association to three amino acid positions (97, 67 and 156) marking three consecutive pockets (C, B and D) within the HLA-B peptide binding groove, explaining 80 12.9% of trait variance, and obviating effects of previously reported associations from 81 population-specific HIV studies.

83 Main

The HLA genes located within the MHC region encode proteins that play essential roles in immune responses including antigen presentation. They account for more heritability than all other variants together for many diseases^{1–4}. It also has more reported GWAS trait associations than any other locus⁵. The extended MHC region spans 6Mb on chromosome 6p21.3 and contains more than 260 genes⁶. Due to population-specific positive selection it harbors unusually high sequence variation, longer haplotypes than most of the genome, and haplotypes

that are specific to individual ancestral populations^{7,8}. Consequently, the MHC is among the most challenging regions in the genome to analyze. Advances in HLA imputation have enabled population-specific association and fine-mapping studies of this locus^{2,9–12}. But despite large effect sizes, fine-mapping in multiple populations simultaneously is challenging without a single large and high-resolution multi-ethnic reference panel. This has caused confusion in some instances. For example, defining the driving HLA alleles may inform the design of antigenic peptides for vaccines^{13,14} for HIV-1, which led to 770,000 deaths in 2018 alone¹⁵. However, multiple risk HLA risk alleles have been independently reported in different populations^{1,10,16}, and it is not clear if they represent truly population-specific signals or are confounded by linkage.

99 Results

100 Performance evaluation of inferred classical HLA alleles

To build a large-scale multi-ethnic HLA imputation reference panel, we used high-coverage whole genome sequencing (WGS) datasets 17-21 from the Japan Biological Informatics Consortium²⁰, the BioBank Japan Project¹⁸, the Estonian Biobank²², the 1000 Genomes Project (1KG)²¹ and a subset of studies in the TOPMed program (**Supplementary Note**, Supplementary Table 1-2). To perform HLA typing using WGS data, we extracted reads 105 mapped to the extended MHC region (chr6:25Mb-35Mb) and unmapped reads from 24,338 106 samples. We applied a population reference graph^{23–25}, for the MHC region to infer classical 107 alleles for three HLA class I genes (HLA-A, -B and -C) and five class II genes (HLA-DQA1, 108 -DQB1, -DRB1, -DPA1, -DPB1) at G-group resolution, which determines the sequences of the 109 exons encoding the peptide binding groove. We required samples to have >20x coverage across all HLA genes (Supplementary Table 1, 3). After quality control our panel included 112 21,546 individuals: 10,187 EUR, 7,849 AA, 2,069 EAS, 952 LAT and 489 SAS.

To assess the accuracy of the WGS *HLA* allele calls, we compared the inferred *HLA* classical alleles to gold standard sequence-based typing (SBT) in 955 1KG subjects and 288 Japanese subjects and quantified concordance. In both cohorts we observed slightly higher average accuracy for class I genes, obtaining 99.0% (one-field, formally known as two-digit), 99.2% (amino acid) and 96.5% (G-group resolution), than class II genes, obtaining 98.7% (one-field), 99.7% (amino acid) and 96.7% (G-group resolution, **Methods, Supplementary Figure 1**, **Supplementary Tables 4-5, Extended Data 1**).

120 HLA diversity

To quantify MHC diversity, we calculated identity-by-descent (IBD) distances²⁶ between all individuals using 38,398 MHC single nucleotide polymorphisms (SNPs) included in the multi-ethnic HLA reference panel (N=21,546) and applied principal component analysis (PCA, Methods). PCA distinguished EUR, EAS and AA as well as the admixed LAT and SAS samples (Figure 1a, Supplementary Figure 2). This reflected widespread HLA allele frequency differences between populations (Figure 1b-c, Supplementary Figure 3). Of 130 unique common (frequency > 1%) G-group alleles, 129 demonstrated significant differences of frequencies across populations (4 degree-of-freedom Chi-square test, p-value < 0.05/130, **Supplementary Figure 4**). The only exception was DQA1*01:01G which was nominally 129 significant (unadjusted p-value = 0.047). These differences may be related to adaptive selection. 130 For example, the B*53:01:01G allele is enriched in Admixed Africans (11.7% in AA versus 0.3% 131 in others) and it has been previously associated with malaria protection 27,28. Consistent with previous reports^{29,30}, we observed that HLA-B had the highest allelic diversity (n=443) while

- 134 HLA-DQA1 had the least (n=17, Supplementary Figure 5-6, Supplementary Table 6,
- 135 Extended Data 1).
- 36 To understand the haplotype structure of HLA between pairs of HLA genes we calculated a
- multiallelic linkage disequilibrium (LD) measurement index $^{31-33}$, ϵ , which is 0 when there is no
- 138 LD and 1 when there is perfect LD (**Figure 2a**). We observed higher ε between *DQA1*, *DQB1*,
- and DRB1; between DPA1 and DPB1; and between B and C (Supplementary Figure 7). The
- 140 heterogeneity between different populations was underscored by the presence of
- 141 population-specific common (frequency >1%) high resolution long-range haplotypes
- 142 (HLA-A~C~B~DRB1~DQA1~DQB1~DPA1~DPB1, Figure 2b, Supplementary Figure 8-12,
- 143 Extended Data 2, Methods). The most common within-population haplotype was A24::DP6
- 144 (HLA-A*24:02:01G~C*12:02:01G~B*52:01:01G~DRB1*15:02:01G~DQA1*01:03:01G~DQB1*06
- 145 :01:01G~DPA1*02:01:01G~DPB1*09:01:01G) found at a frequency of 3.61% in EAS
- 146 (Supplementary Figure 8). This haplotype is strongly associated with immune-mediated traits
- such as HIV³⁴ and ulcerative colitis³⁵ in Japanese individuals. The next most common haplotype
- 148 was the well-described European-specific ancestral haplotype A1::DP1 or 8.1^{36,37} (
- 149 frequency=2.76%,
- 150 HLA-A*01:01G~C*07:01:01G~B*08:01:01G~DRB1*03:01:01G~DQA1*05:01:01G~DQB1*02:
- 151 01:01G~DPA1*02:01:02G~DPB1*01:01:01G, **Supplementary Figure 9**). This haplotype is
- 152 associated with diverse immunopathological phenotypes in the European population, including
- 153 systemic lupus erythematosus³⁸, myositis³⁹ and several other conditions³⁶. We observed
- 154 long-range haplotypes in admixed populations including A1::DP4 in SAS (frequency=1.86%,
- 155 **Supplementary Figure 10**), A30::DP1 in AA (frequency=1.18%,
- 156 HLA-A*30:01:01G~C*17:01:01G~B*42:01:01:G~DRB1*03:02:01G~DQA1*04:01:01G~DQB1*04

- 157 :02:01G~DPA1*02:02:02G~DPB1*01:01:01G , Supplementary Figure 11), and A29::DP11 in
- 158 LAT (frequency=0.74%,
- 159 HLA-A*29:02:01G~C*16:01:01G~B*44*03:01:G~DRB1*07:01:01G~DQA1*02:01:01G~DQB1*0
- 160 2:01:01G~DPA1*02:01:01G~DPB1*11:01:01G, Supplementary Figure 12).
- 161 These haplotypes also have associations with multiple diseases: for example C*06:02~B*57:01
- 162 is associated with psoriasis⁴⁰ and A*30:01~C*17:01~B*42:01 is associated with HIV⁴¹.
- 163 HLA selection signature
- Previous studies have suggested that recent natural selection favors African ancestry in the HLA region in admixed populations^{42–45}. To test this hypothesis in our data, we obtained WGS data from a subset of individuals within two admixed populations (1,832 AA and 594 LAT, determined by the first three global principal components, Supplementary Figure 13, Supplementary Note). Admixed individuals have genomes that are a mosaic of different ancestries. If genetic variations or haplotypes from an ancestral population are advantageous, then they are under selection and are expected to have higher frequency than by chance. Using 171 ELAl⁴⁶, we quantified how much the ancestry proportions differed within the MHC from the genome-wide average. In AA, we observed that the average genome-wide proportion of African ancestry was 74.5%, compared to 78.0% in the extended MHC region, corresponding to a 3.42 (95% CI: 3.35-3.49) standard deviation increase. In LAT, we observed 5.76% African ancestry genome-wide versus 16.0% in the extended MHC region, representing an increase of 4.23 175 (95% CI: 4.14-4.31) standard deviations (Methods, Supplementary Figure 14). To ensure our results are robust to different local ancestry inference methods, we applied an alternative 177 method called RFMix⁴⁷ and observed a similarly consistent MHC-specific excess of African ancestry in LAT, and also an excess in AA that was more modest (Supplementary Figure 14).

Construction of a multi-ethnic HLA reference panel and its performance evaluation Next, we constructed a multi-ethnic HLA imputation reference panel based on classical HLA 181 alleles and 38,398 genomic markers in the extended MHC region using a novel HLA-focused 182 pipeline HLA-TAPAS (HLA-Typing At Protein for Association Studies). Briefly, HLA-TAPAS can 183 handle HLA reference panel construction (MakeReference); HLA imputation (SNP2HLA) and 184 HLA association (HLAassoc) (Methods, URLs). Compared to a widely used HLA reference panel with European-only individuals (The Type 1 Diabetes Genetics Consortium⁴⁸, T1DGC), this new reference panel has a six-fold increase in the number of observed HLA alleles and 187 non-HLA genomic markers (Supplementary Table 7). We noted the difference in observed 188 classical HLA alleles is mainly due to the inclusion of diverse populations rather than its size; 189 after downsampling the reference panel to be the same size as T1DGC (N=5,225), there was 190 still a three-fold increase in observed alleles (**Figure 3a**).

To empirically assess imputation accuracy of our reference panel, we first used the publicly
available gold-standard *HLA* types (HLA-*A*, -*B*,-*C*, -*DRB1* and -*DQB1*) of 1,267 diverse samples
from AA, EAS, EUR and LAT included in 1KG. We removed 955 overlapping samples within the
reference panel, and to ensure a representative analysis we kept 6,007 markers overlapping
with the *Global Genotyping Array* SNPs. Across the five genes, the average G-group resolution
accuracies were 94.2%, 93.7%, 97.8% and 93.7% in AA, EAS, EUR and LAT (**Figure 3b-c**, **Supplementary Table 8, Methods, Extended Data 3**). Compared to the T1DGC panel, our
multi-ethnic reference panel showed the most improvement for individuals of non-European
descent; we obtained 4.27%, 2.96%, 2.90% and 1.05% improvement at G-group resolution for
AA, EAS, LAT, and EUR individuals, respectively (**Figure 3d**). Increased diversity was

202 responsible for the improvement; downsampling the reference panel be the same size as the T1DGC panel still yielded superior performance (Figure 3d). To validate our panel further, we 203 imputed HLA alleles into a multi-ethnic cohort of 2,291 individuals from the Genotype and 205 Phenotype (GaP) registry genotyped on the ImmunoChip array. We obtained SBT HLA type information for six classical class I and class II loci (HLA-A, -B, -C, -DQA1, -DQB1, -DRB1) in 75 206 samples with diverse ancestral background (25 EUR, 25 EAS and 25 AA, Supplementary 207 Figure 15, Methods). Average accuracies were 99.0%, 95.7% and 97.0% for EUR, EAS and 208 AA respectively when comparing SBT HLA alleles at G-group resolution (Methods, Extended 209 Data 3). Similar to the 1KG analysis, the multi-ethnic reference panel showed significant 210 improvement for individuals with non-European descent (6.3% and 11.1% improvement for EAS 211 and African individuals respectively at G-group resolution), and a more modest 2% improvement 212 in EUR (Supplementary Figure 16, Supplementary Table 9). 214 Fine-mapping causal variants of HIV jointly in three populations in the MHC region Next we investigated MHC effects within human immunodeficiency virus type 1 (HIV-1) set point viral load. Upon primary infection with HIV-1, the set point viral load is reached after the immune system has developed specific cytotoxic T lymphocytes (CTL) that are able to partially control the virus. It has been well-established that the set point viral load (spVL) varies in the infected population and positively correlates with rate of disease progression⁴⁹. Previous studies 219 suggested that HIV-1 infection has a strong genetic component, and specific HLA class I alleles 220 explain the majority of genetic risk^{10,50}. The existence of multiple independent, ancestry-specific, 221 risk-associated alleles has been reported in both European^{1,10} and African American¹⁶ 222 populations. However, without a multi-ethnic reference panel it has not been possible to 223 determine if these signals are consistent across different ancestral groups.

To define the MHC allelic effects shared across multiple populations, we applied our multi-ethnic MHC reference panel to 7,445 EUR, 3,901 AA and 677 LAT HIV-1 infected subjects (Methods, Supplementary Table 10). Imputation resulted in 640 classical HLA alleles, 4,513 amino acids 227 in HLA proteins and 49,321 SNPs in the extended MHC region for association and fine-mapping analysis. We confirmed 96.6% imputation accuracy of two-field (or four-digit) resolution with a 229 minor allele frequency > 0.5% in this cohort by comparing imputed classical alleles to the SBT 230 231 alleles in a subset of 1,067 AA subjects¹⁶(Supplementary Figure 17, Extended Data 3). We next tested SNPs, amino acid positions and classical HLA alleles across the MHC for association to spVL. We performed this jointly in EUR, AA and LAT population using a linear 233 regression model with sex, principal components and ancestry as covariates (Methods). In 234 agreement with previous studies, we found the strongest spVL-associated classical HLA allele 235 is B*57 (effect size = -0.84, $P_{binary} = 8.68 \times 10^{-144}$). This corresponded to a single residue Val97 236 in HLA-B that tracks almost perfectly with B*57 ($r^2 = 0.995$) and showed the strongest 237 association of any single residue (effect size = -0.84, $P_{binary} = 5.99 \times 10^{-145}$, **Supplementary** Figure 18). 239 Then to determine which amino acid positions have independent association with spVL, we tested each of the amino acid positions by grouping haplotypes carrying a specific residue at each position in an additive model^{2,9} (**Methods**). We found the strongest spVL-associated amino 242 acid variant in HLA-B is as previously reported 1,10,16 at position 97 (Figure 4a-b, Supplementary 243 **Table 11**) which strikingly explains 9.06% of the phenotypic variance. Position 97 in HLA-B was more significant ($P_{\it omnibus} = 2.86 \times 10^{-184}~$) than any single SNP or classical *HLA* allele, including

246 B*57 (Supplementary Figure 18, Extended Data 4). Of the six allelic variants (Val/Asn/Trp/Thr/Arg/Ser) at this position, the Val residue conferred the strongest protective effect (effect size = -0.88, $P = 9.32 \times 10^{-152}$, **Supplementary Figure 19**) relative to the most 248 common residue Arg (frequency = 47.8%). All six amino acid alleles have consistent 249 frequencies and effect sizes across the three population groups (Figure 5a-b, Supplementary 250 251 Figure 20). We next wanted to test whether there were other independent effects outside of position 97 in 252 HLA-B. After accounting for the effects of amino acid 97 in HLA-B using a conditional haplotype 253 254 analysis (**Methods**), we observed a significant independent association at position 67 in HLA-B ($P_{omnibus} = 2.82 \times 10^{-39}$, Figure 4c-d, Supplementary Table 11). Considering this might be an 255 artifact of forward search, we exhaustively tested all possible pairs of polymorphic amino acid positions in HLA-B. Of 7,260 pairs of amino acid positions, none obtained a better 257 goodness-of-fit than the pair of positions 97 and 67, which collectively explained 11.2% variance 258 in spVL (Figure 5e, Supplementary Table 12). At position 67, Met67 residue shows the most 259 protective effect (effect size = -0.44, $P = 1.19 \times 10^{-59}$) among the five possible amino acids 260 (Cys/Phe/Met/Ser/Tyr) relative to the most common residue Ser (frequency =10.0%). 261 Conditioning on positions 97 and 67 revealed an additional association at position 156 in HLA-B ($P_{omnibus} = 1.92 \times 10^{-30}$, Figure 4e-f, Supplementary Table 11). In agreement with the stepwise conditional analysis, when we tested all 287,980 possible combinations of three amino acid positions in HLA-B, the most statistically significant combination of amino acids sites is 67, 265 97 and 156 ($P = 5.68 \times 10^{-244}$, **Supplementary Table 13**). These three positions explained 266 267 12.9% of the variance (Figure 5e). At position 156, residue Arg shows the largest risk effect

(effect size = 0.180, $P = 8.92 \times 10^{-14}$) among the four possible allelic variants (Leu/Arg/Asp/Trp), relative to the most common residue Leu (frequency = 35.1%). These amino acid positions mark three consecutive pockets within the HLA-B peptide-binding 270 groove (Figure 5c). Position 97 is located in the C-pocket and has an important role in 271 determining the specificity of the peptide-binding groove^{51,52}. Position 67 is in the B-pocket, and Met67 side chains occupy the space where larger B-pocket anchors reside in other 273 peptide-MHC structures; its presence limits the size of potential peptide position P2 side 274 chains⁵². Amino acid position 156 is part of the D-pocket and influences the conformation of the 276 peptide-binding region⁵³. These results are consistent with the observation that in HLA-B*57, the single most protective spVL-associated one-field allele (a single change at position 156 from Leu \rightarrow Arg or equivalently HLA-B*57:03 \rightarrow HLA-B*57:02) leads to an increased repertoire of HIV-specific epitope^{41,54}. Despite differences in the power to detect associations due to differences in allele frequencies 280 (Supplementary Figure 21), we observed generally consistent effects of individual residues 281 across populations (Figure 5d, Supplementary Figure 22-23, Supplementary Table 14). 282 There are 26 unique haplotypes defined by the amino acids at positions 67, 97 and 156 in 283 HLA-B (Table 1, Supplementary Table 15). When we tested for effect size heterogeneity by 284 ancestry for each of these haplotypes (**Methods**), we observed only 2 of 26 haplotypes showed 285 heterogeneity (F-test P-value < 0.05/26), possibly due to different interplay between genetic and 286 environmental variation at population-level. These results support the concept that these 287 positions mediate HIV-1 viral load in diverse ancestries.

To assess whether there were other independent MHC associations outside HLA-B, we conditioned on all amino acid positions in HLA-B and observed associations at HLA-A, including at position 77 in HLA-A ($P_{omnibus} = 9.10 \times 10^{-7}$, **Figure 4g-h**, **Supplementary Table 11**), the classical *HLA* allele *HLA-A*31* ($P_{binary} = 2.45 \times 10^{-8}$) and the *rs2256919* promoter SNP ($P_{binary} = 3.10 \times 10^{-16}$, **Supplementary Figure 18**). These associations argue for an effect at HLA-A, but larger studies and functional studies will be necessary to define the driving effects.

Discussion

In our study we demonstrated accurate imputation with a single large reference panel for HLA imputation. We have shown how this reference panel can be used to impute genetic variation at eight *HLA* classical genes accurately across a wide range of populations. Accurate imputation in multi-ethnic studies is essential for fine-mapping.

We showed the utility of this approach by defining the alleles that best explain HIV-1 viral load in infected individuals. Our work implicates three amino acid positions (97, 67 and 156) in HLA-B 301 in conferring the known protective effect of HLA class I variation on HIV-1 infection. Combining 302 all alleles at these three positions explained 12.9% of the variance in spVL (Figure 5e). These 303 positions all fall within the peptide-binding groove of the respective MHC protein (Figure 5c), 304 indicating that variation in the amino acid content of the peptide-binding groove is the major 305 genetic determinant of HIV control. Supported by experimental studies^{54–57}, positions highlighted in our work indicated a structural basis for the HLA association with HIV disease progression 307 that is mediated by the conformation of the peptide within the class I binding groove. This result 308 highlights how a study with ancestrally diverse populations can potentially point to causal 309 310 variation by leveraging linkage disequilibrium difference between ethnic groups.

We note that previous studies have shown position 97 in HLA-B has the strongest association with HIV-1 spVL or case-control in African American and European populations, but highlighted different additional signals via conditional analysis (position 45, 67 in HLA-B and position 77, 95 in HLA-A in Europeans^{1,10,16} and position 63, 116 and 245 in HLA-B in African Americans¹⁶). These signals do not explain the signals we report here; after conditioning on positions 45, 63, 116, 245 of HLA-B and 95 of HLA-A, the association of the four identified amino acids identified in this study remained significant ($P < 5 \times 10^{-8}$). In contrast, our binding groove alleles explain these other alleles; conditioning on the four amino acid positions identified in this study (positions 67, 97 and 156 in HLA-B), all previously reported positions did not pass the significance threshold ($P > 5 \times 10^{-8}$, **Supplementary Figure 24**).

Furthermore, defining the effect sizes for *HLA* alleles across different populations is essential for defining risk of a wide-range of diseases in the clinical setting. There is increasing application of genome-wide genotyping by patients both by healthcare providers and direct-to-consumer vendors. The large effects of the MHC region for a wide-range of immune and non-immune traits, makes it essential to define *HLA* allelic effect sizes essential in multi-ethnic studies in order to build generally applicable clinical polygenic risk scores for many diseases in diverse populations^{58–61}. Resources like the one we present here will be an essential ingredient in such studies.

329 Methods

330 Individuals included in the reference panel

Study participants were from the Jackson Heart Study (JHS, N = 3,027), Multi-Ethnic Study of
Atherosclerosis (MESA, N=4,620), Chronic Obstructive Pulmonary Disease Gene (COPDGene)
study (N=10,623), Estonian Biobank (EST, N=2,244), Japan Biological Informatics Consortium
(JPN, N=295), Biobank Japan (JPN, N=1,025) and 1000 Genomes Project (1KG, N=2,504).
Each study was previously approved by respective institutional review boards (IRBs), including
for the generation of WGS data and association with phenotypes. All participants provided
written consent. Further details of cohort descriptions and phenotype definitions are described in
the **Supplementary Note**.

339 HLA-TAPAS

HLA-TAPAS (HLA-Typing At Protein for Association Studies) is an HLA-focused pipeline that
can handle HLA reference panel construction (*MakeReference*), HLA imputation (*SNP2HLA*),
and HLA association (*HLAassoc*). It is an updated version of the SNP2HLA⁴⁸ to build an
imputation reference panel, perform *HLA* classical allele, amino acid and SNP imputation within
the extended MHC region. Briefly, major updates include (1) using PLINK1.9 (**URLs**) instead of
v1.07; (2) using BEAGLE v4.1 (**URLs**) instead of v3 for phasing and imputation; and (3)
including custom R scripts for performing association and fine-mapping analysis at amino acid
level in multiple ancestries. The source code is available for download (**URLs**).

Construction of a multi-ethnic HLA reference panel using whole-genome sequences

To construct a multi-ethnic HLA imputation reference panel, we used 24,338 whole-genome sequences at different depths (**Supplementary Table 1**). Details of the construction using deep-coverage whole-genome sequencing are described in the **Supplementary Note**. Briefly, alignment and variant-calling for genomes sequenced by each cohort were performed independently. We performed local realignment and quality recalibration with the Genome Analysis Toolkit⁶² (GATK; version 3.6) on Chromosome 6:25,000,000-35,000,000. We detected single nucleotide variants (SNV) and indels using GATK with HaplotypeCaller. To eliminate false-positive sites called in the MHC region, we restrict our panel to SNVs reported in 1000 Genomes Project²¹ only.

We next inferred classical HLA alleles at G-group resolution for eight classical HLA genes

(HLA-A, -B, -C, -DQA1, -DQB1, -DRB1, -DPA1 and -DPB1) using a population reference

graph^{24,25}. To extend the reference panel versatility, we inferred amino acid variation, one-field

and two-field resolution alleles from the inferred G-group alleles. After removing samples with

low-coverage and failed genome-wide quality control (Supplementary Table 3), we constructed

a multi-ethnic HLA imputation reference panel (N=21,546) using the HLA-TAPAS

MakeReference module (URLs, Method).

- 366 Sequence-based typing of HLA alleles
- Purified DNA from the 75 donors from the GaP registry (at the Feinstein Institute for Medical
- 368 Research) was sent to NHS Blood and Transplant, UK, where HLA typing was performed.
- Next-generation sequencing was done for HLA-A, -B, -C, -DQB1, -DPB1 and -DRB1.
- 370 PCR-sequence-specific oligonucleotide probe sequencing was performed for HLA-DQA1 in all
- 371 samples. These typing methods yielded classical allele calls for seven genes at three-field
- 372 (HLA-A, -B, -C and -DQB1) or G-group resolution (HLA-DQA1, -DPB1 and -DRB1).
- 373 Genomic DNA from the 288 unrelated samples of Japanese ancestry underwent high-resolution
- 374 allele typing (three-field alleles) of six classical HLA genes (HLA-A, -B and -C for class I; and
- 375 HLA-DRB1, -DQA1 and -DPB1 for class II)²⁰.
- 376 The 1000 Genomes panel consists of 1,267 individuals with information on five HLA genes
- 377 (HLA-A, -B, -C, -DQB1, and -DRB1) at G-group resolution among four major ancestral groups
- 378 (AA, EAS, EUR and LAT)⁷.
- 379 We obtained HLA typing of the 1,067 African American subjects included in the HIV-1 viral load
- 380 study as described previously 16,63. Briefly, seven classical HLA genes (HLA-A, -B, -C, -DQA1,
- 381 -DQB1 -DRB1 and -DPB1) were obtained by sequencing exons 2 and 3 and/or single-stranded
- 382 conformation polymorphism PCR, and was provided at two-field resolution.

Accuracy measure between inferred and sequence-based typing *HLA*384 genotypes

Allelic variants at HLA genes can be typed at different resolutions: one-field HLA types specify serological activity, two-field HLA types specify the amino acids encoded by the exons of the HLA gene, and three-field types determine the full exonic sequence including synonymous variants. G-group resolution determines the sequences of the exons encoding the peptide binding groove, that is, exons 2 and 3 for class I and exon 2 class II genes. Thus, any polymorphism occurring in exon 4 of class I gene or exon 3 of class II gene was not defined.

This means many G-group alleles can map to multiple three-field and two-field *HLA* alleles.

We calculated the accuracy at each *HLA* gene by summing across the dosage of each correctly inferred *HLA* allele or amino acid across all individuals (N), and divided by the total number of observations (2*N). That is,

$$Accuracy(g) = \frac{\sum\limits_{i}^{N} D_{i}(A_{IIg}) + D_{i}(A_{2ig})}{2N},$$

where Accuracy(g) represents the accuracy at a classical HLA gene (e.g. HLA-B). D_i represents the inferred dosage of an allele in individual i, and alleles $A_{1i,g}$ and $A_{2i,g}$ represent the true (SBT) HLA types for an individual i.

To evaluate the accuracy between the inferred and validated *HLA* types obtained from SBT at
G-group resolution, we translated the highest resolution specified by the validation data to its
matching G-group resolution based IMGT/HLA database (e.g. HLA-*A*01:01* →
HLA-*A*01:01:01G*), and compared it to the primary output from *HLA*LA* or *HLA-TAPAS*. We

- also translated all G-group alleles to their matching amino acid sequences, and compared them against the validation alleles, we referred to this as the amino acid level.
- To evaluate imputation performance in individual classical *HLA* alleles and amino acids, we calculated the dosage r^2 correlation between imputed and SBT dosage.

$$407 \quad r^{2} = \left[\sum_{i=1}^{N} x_{i} y_{i} - \left(\sum_{i=1}^{N} x_{i} \right) \left(\sum_{i=1}^{N} y_{i} \right) / N \right]^{2} / \left[\left(\sum_{i=1}^{N} x_{i}^{2} - \left(\sum_{i=1}^{N} x_{i} \right)^{2} / N \right) \left(\sum_{i=1}^{N} y_{i}^{2} - \left(\sum_{i=1}^{N} y_{i} \right)^{2} / N \right) \right]$$

- 408 where x_i and y_i represents the inferred and SBT dosage of an allele in individual i. N 409 represents the number of individuals.
- 410 Principal component analysis
- We performed a principal component analysis of the MHC region based on the identity-by-descent (IBD) distances between all 21,809 individuals included in the multi-ethnic reference panel. We computed the IBD distance using Beagle (Version 4.1, **URLs**) and averaged over 100 runs with all variants (54,474) included in the HLA reference panel. Due to uneven representation of different ethnicity groups (**Supplementary Table 2**), we applied a weighted PCA approach, where mean and standard deviation of the IBD matrix within an

ethnicity group are weighted inversely proportional to the sample size.

- 418 HLA haplotype frequency estimation
- We applied an expectation-maximization algorithm approach implemented in Hapl-o-Mat⁶⁴

 (URLs) to estimate HLA haplotype frequency based on eight classical HLA alleles inferred at

 G-group resolution. We estimated haplotype frequencies both overall and within five continental

 populations (Extended Data 2).

423 Local ancestry inference

To detect local ancestry in admixed samples, we first applied ELAI⁴⁶ to chromosome 6 with 1000 Genomes Project²¹ as the reference panel. We extracted 63,998 common HapMap3 SNPs between the WGS (MESA cohort) and the 1000 Genome reference panel. We used the same set of SNPs for ELAI and RFMix analysis. We applied ELAI⁴⁶ to 1,832 African Americans and 427 594 Latinos. For 1,832 African American individuals included in the study, we used genotypes of 99 CEU and 108 YRI in the 1000 Genome Project as reference panel, assuming admixture 429 generation to be seven generations ago. We used two upper-layer clusters and 10 lower-layer clusters in the model. For Latinos, we selected 65 Latinos with Native American (NAT) ancestry 431 > 75% included in the 1000 Genomes Project identified using the ADMIXTURE analysis 65 and used these individuals with high NAT, as well as CEU and YRI from 1000 Genomes as 433 reference panels. We assumed that the admixture time was 20 generations ago. For ELAI, we 434 used three upper-layer clusters and 15 lower-layer clusters in the model.

To address the technical concerns that local ancestry methods are biased by the high LD of MHC region^{66,67}, we performed an alternative method, RFMix⁴⁷, for local ancestry inference that accounts for high LD and lack of parental reference panels. Similar deviation from genome-wide ancestry was observed using RFMix (**Supplementary Figure 14**), indicating that the selection signals we observed here are robust to different inference methods.

HLA imputation in the HIV-1 viral load GWAS data in three populations
We used genome-wide genotyping data from 12,023 HIV-1 infected individuals aggregated
across more than 10 different cohorts (**Supplementary Table 10**). The details of these samples
and quality control procedures have been described previously^{10,68}. Using the HIV-1 viral load
GWAS data, we extracted the genotypes of SNPs located in the extended MHC region
(chr6:28-34Mb, **Supplementary Table 10**). We conducted genotype imputation of one-field,
two-field and G-group classical *HLA* alleles and amino acid polymorphisms of the eight class I
and class II HLA genes using the constructed multi-ethnic HLA imputation reference panel and
the HLA-TAPAS pipeline.

After imputation, we obtained the genotypes of 640 classical alleles, 4,513 amino acid positions of the eight classical HLA genes, and 49,321 SNPs located in the extended MHC region. We excluded variants with MAF < 0.5% and imputation $r^2 < 0.5$ for all association studies. In total, we tested 51,358 variants in our association and fine-mapping study.

454 HLA association analysis

For the HIV-1 viral loads of EUR, AA and LAT samples, we conducted a joint haplotype-based association analysis using a linear regression model under the assumption of additive effects of the number of HLA haplotypes for each individual. Phased haplotypes at a locus (i.e., HLA amino acid position) were constructed from the phased imputed genotypes of variants in the locus (i.e., amino acid change or SNP) and were converted to a haplotype matrix where each row is observed haplotypes (in the locus), not genotypes.

For each amino acid position, we applied a conditional haplotype analysis. We tested a
multiallelic association between the HIV-1 viral load and a haplotype matrix (of the position) with
covariates, including sex, study-specific PCs, and a categorical variable indicating a population.
That is

$$y = \beta_0 + \sum_{i}^{m-1} \beta_{1i} x_i + \sum_{j}^{C} \beta_{2j} c_j,$$

where x_i is the amino acid haplotype formed by each of the m amino acid residues that occur at that position, and c_i are the covariates included in the model.

To get an omnibus P-value for each position, we estimated the effect of each amino acid by assessing the significance of the improvement in fit by calculating the in-model fit, compared to a null model following an F-distribution with m-1 degrees of freedom. This is implemented using an ANOVA test in R as described previously^{32,69}. The most frequent haplotype was excluded from a haplotype matrix as a reference haplotype for association.

For the conditional analysis, we assumed that the null model consisted of haplotypes as defined by residues at previously defined amino acid positions. The alternative model is in addition of another position with m residues. We tested whether the addition of those amino acid positions, and the creation of k additional haplotypes groups, improved on the previous set. We then assessed the significance of the improvement in the delta deviance (sum of squares) over the previous model using an F-test. We performed stepwise conditional analysis to identify additional independent signals by adjusting for the most significant amino acid position in each step until none met the significance threshold ($P = 5 \times 10^{-8}$). We restricted

analysis to haplotypes that have a minimum of 10 occurrences within HLA-B, and removed any

For the exhaustive search, we tested all possible amino acid pairs and triplets for association.

484 For each set of amino acid positions, we used the groups of residues occurring at these

485 positions to estimate effect size and calculated for each of these models the delta deviance in

486 risk prediction and its p-values compared to the null model.

individual with rare haplotypes for the conditional analysis.

487 Heterogeneity testing of effect sizes

488 We used interaction analyses with models that included haplotype-by-ancestry (Haplotype x

489 Ancestry) interaction terms. The fit of nested models was compared to a null model using the

490 F-statistic with two degrees of freedom, for which the association interaction P-value indicated

491 whether the inclusion of the *Haplotype x Ancestry* interaction terms improved the model fit

492 compared to the null model that did not include the interaction terms. Interaction P-values for all

493 haplotypes formed by positions 97, 67 and 156 in HLA-B are listed in **Supplementary Table 15**.

494 Haplotypes that had a significant Bonferroni-corrected Haplotype x Ancestry interaction

495 heterogeneity P-value (P < 0.05/26) were considered to show evidence of significant effect size

96 heterogeneity between ancestries.

URLs

- 498 HLA-TAPAS, https://github.com/immunogenomics/HLA-TAPAS
- 499 IMGT/HLA, https://www.ebi.ac.uk/ipd/imgt/hla/;
- 500 GATK version 3.6, https://software.broadinstitute.org/gatk/download/archive;
- 501 HLA*LA, https://github.com/DiltheyLab/HLA-PRG-LA;

- 502 PLINK 1.90, https://www.cog-genomics.org/plink2;
- 503 Beagle 4.1, https://faculty.washington.edu/browning/beagle/b4 1.html;
- 504 Hapl-o-Mat, https://github.com/DKMS/Hapl-o-Mat/;
- 505 1000 Genomes gold-standard HLA types,
- 506 http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/data_collections/HLA_types/

507 Acknowledgements

- 508 The study was supported by the National Institutes of Health (NIH) TB Research Unit Network,
- 509 Grant U19 Al111224-01.
- 510 The views expressed in this manuscript are those of the authors and do not necessarily
- 511 represent the views of the National Heart, Lung, and Blood Institute; the National Institutes of
- 512 Health; or the U.S. Department of Health and Human Services.
- 513 The Genotype and Phenotype (GaP) Registry at The Feinstein Institute for Medical Research
- 514 provided fresh, de-identified human plasma; blood was collected from control subjects under an
- 515 IRB-approved protocol (IRB# 09-081) and processed to isolate plasma. The GaP is a
- 516 sub-protocol of the Tissue Donation Program (TDP) at Northwell Health and a national resource
- 517 for genotype-phenotype studies.
- 518 https://www.feinsteininstitute.org/robert-s-boas-center-for-genomics-and-human-genetics/gap-re
- 519 **gistry/**
- 520 A.M. is supported by Gentransmed grant 2014-2020.4.01.15-0012.; D.W.H. is supported by
- 521 NIH grants Al110527, Al077505, TR000445, Al069439, and Al110527. D.H.S. was supported by

R01 HL92301, R01 HL67348, R01 NS058700, R01 AR48797, R01 DK071891, R01 AG058921, the General Clinical Research Center of the Wake Forest University School of Medicine (M01 523 RR07122, F32 HL085989), the American Diabetes Association, and a pilot grant from the Claude Pepper Older Americans Independence Center of Wake Forest University Health Sciences (P60 AG10484). J.T.E. and P.E.S. were supported by NIH/NIAMS R01 AR042742, R01 AR050511, and R01 AR063611. 527 For some HIV cohort participants, DNA and data collection was supported by NIH/NIAID AIDS Clinical Trial Group (ACTG) grants UM1 Al068634, UM1 Al068636 and UM1 Al106701, and 529 ACTG clinical research site grants A1069412, A1069423, A1069424, A1069503, Al025859, 530 AI025868, AI027658, AI027661, AI027666, AI027675, AI032782, AI034853, AI038858, 531 AI045008, AI046370, AI046376, AI050409, AI050410, AI050410, AI058740, AI060354, 532 533 Al068636, Al069412, Al069415, Al069418, Al069419, Al069423, Al069424, Al069428, AI069432, AI069432, AI069434, AI069439, AI069447, AI069450, AI069452, AI069465, 534 AI069467, AI069470, AI069471, AI069472, AI069474, AI069477, AI069481, AI069484, 535 AI069494, AI069495, AI069496, AI069501, AI069501, AI069502, AI069503, AI069511, 536 537 AI069513, AI069532, AI069534, AI069556, AI072626, AI073961, RR000046, RR000425, RR023561, RR024156, RR024160, RR024996, RR025008, RR025747, RR025777, RR025780, 538 TR000004, TR000058, TR000124, TR000170, TR000439, TR000445, TR000457, TR001079, 539 TR001082, TR001111, and TR024160. Molecular data for the Trans-Omics in Precision Medicine (TOPMed) program was supported by the National Heart, Lung and Blood Institute (NHLBI). See the TOPMed Omics Support Table 543 (**Supplementary Table 16**) for study specific omics support information. Core support including

centralized genomic read mapping and genotype calling, along with variant quality metrics and filtering were provided by the TOPMed Informatics Research Center (3R01HL-117626-02S1; contract HHSN268201800002I). Core support including phenotype harmonization, data management, sample-identity QC, and general program coordination were provided by the TOPMed Data Coordinating Center (R01HL-120393; U01HL-120393; contract 548 HHSN2682018000011). We gratefully acknowledge the studies and participants who provided 549 biological samples and data for TOPMed. The COPDGene project was supported by Award Number U01 HL089897 and Award Number 551 U01 HL089856 from the National Heart, Lung, and Blood Institute. The content is solely the 552 responsibility of the authors and does not necessarily represent the official views of the National 553 Heart, Lung, and Blood Institute or the National Institutes of Health. The COPDGene project is 554 also supported by the COPD Foundation through contributions made to an Industry Advisory 555 Board comprised of AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer, 556 Siemens and Sunovion. A full listing of COPDGene investigators can be found at: 557 http://www.copdgene.org/directory 558 The Jackson Heart Study (JHS) is supported and conducted in collaboration with Jackson 559 State University (HHSN268201800013I), Tougaloo College (HHSN268201800014I), the 560 Mississippi State Department of Health (HHSN268201800015I) and the University of Mississippi 561 Medical Center (HHSN268201800010I, HHSN268201800011I and HHSN268201800012I) contracts from the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute on Minority Health and Health Disparities (NIMHD). The authors also wish to thank the staffs 565 and participants of the JHS.

MESA and the MESA SHARe project are conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA investigators. Support for MESA is 567 568 provided by contracts 75N92020D00001, HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-HC-95160, 75N92020D00002, N01-HC-95161, 75N92020D00003, 569 N01-HC-95162, 75N92020D00006, N01-HC-95163, 75N92020D00004, N01-HC-95164, 570 75N92020D00007, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, 571 N01-HC-95169, UL1-TR-000040, UL1-TR-001079, UL1-TR-001420. MESA Family is conducted 572 and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with 573 MESA investigators. Support is provided by grants and contracts R01HL071051, 574 R01HL071205, R01HL071250, R01HL071251, R01HL071258, R01HL071259, by the National 575 Center for Research Resources, Grant UL1RR033176. The provision of genotyping data was 576 supported in part by the National Center for Advancing Translational Sciences, CTSI grant 577 UL1TR001881, and the National Institute of Diabetes and Digestive and Kidney Disease 578 Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes 579 Endocrinology Research Center. This project has been funded in whole or in part with federal 580 581 funds from the Frederick National Laboratory for Cancer Research, under Contract No. HHSN261200800001E. The content of this publication does not necessarily reflect the views or 582 policies of the Department of Health and Human Services, nor does mention of trade names, 583 commercial products, or organizations imply endorsement by the U.S. Government. This Research was supported in part by the Intramural Research Program of the NIH, Frederick National Lab, Center for Cancer Research.

587 Author contributions

- 588 Y. L. and S.R. conceived, designed and performed analyses, wrote the manuscript and
- 589 supervised the research. M.K. implemented the omnibus test for the HIV-1 fine-mapping study.
- 590 Y.L., W.C., M.K., P.E.S., J.T.E., and B.H. contributed to the development of the HLA-TAPAS
- 591 pipeline. X.L. performed the selection analysis. J.T.E, M.G.-A. and P.K.G helped with the GaP
- 592 data acquisition. K.Y., K.O., D.W.H., X.G., N.D.P., Y.I.C., J.I.R., K.D.T., S.S.R., A.C., J.G.W.,
- 593 S.K., M.H.C., A.M., T.E., and Y.O. contributed to the WGS data acquisition. J.F., M.C. and P.J.M.
- 594 contributed to the HIV-1 data acquisition. All authors contributed to the writing of the manuscript.

595 Competing interests

- 596 M.H.C. has received consulting or speaking fees from Illumina and AstraZeneca, and grant
- 597 support from GSK and Bayer.

598 References

- 599 1. International HIV Controllers Study *et al.* The major genetic determinants of HIV-1 control
- affect HLA class I peptide presentation. Science 330, 1551–1557 (2010).
- 601 2. Raychaudhuri, S. et al. Five amino acids in three HLA proteins explain most of the
- association between MHC and seropositive rheumatoid arthritis. *Nat. Genet.* **44**, 291–296
- 603 (2012).
- 604 3. Evans, D. M. et al. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis
- implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. *Nat.*
- 606 Genet. **43**, 761–767 (2011).
- 607 4. Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N.
- 608 Engl. J. Med. **371**, 2189–2199 (2014).

- 609 5. Buniello, A. et al. The NHGRI-EBI GWAS Catalog of published genome-wide association
- studies, targeted arrays and summary statistics 2019. *Nucleic Acids Research* vol. 47
- 611 D1005–D1012 (2019).
- 612 6. Horton, R. et al. Gene map of the extended human MHC. Nat. Rev. Genet. 5, 889–899
- 613 (2004).
- 614 7. Gourraud, P.-A. et al. HLA diversity in the 1000 genomes dataset. PLoS One 9, e97282
- 615 (2014).
- 616 8. Robinson, J. et al. IPD-IMGT/HLA Database. Nucleic Acids Res. 48, D948–D955 (2020).
- 617 9. Hu, X. et al. Additive and interaction effects at three amino acid positions in HLA-DQ and
- 618 HLA-DR molecules drive type 1 diabetes risk. *Nat. Genet.* **47**, 898–905 (2015).
- 10. McLaren, P. J. et al. Polymorphisms of large effect explain the majority of the host genetic
- 620 contribution to variation of HIV-1 virus load. *Proc. Natl. Acad. Sci. U. S. A.* **112**,
- 621 14658–14663 (2015).
- 622 11. Tian, C. et al. Genome-wide association and HLA region fine-mapping studies identify
- 623 susceptibility loci for multiple common infections. *Nat. Commun.* **8**, 599 (2017).
- 624 12. Onengut-Gumuscu, S. et al. Type 1 Diabetes Risk in African-Ancestry Participants and
- 625 Utility of an Ancestry-Specific Genetic Risk Score. *Diabetes Care* **42**, 406–415 (2019).
- 626 13. Matthews, P. C. et al. Central role of reverting mutations in HLA associations with human
- immunodeficiency virus set point. *J. Virol.* **82**, 8548–8559 (2008).
- 628 14. Wang, Y. Development of a human leukocyte antigen-based HIV vaccine. F1000Res. 7,
- 629 (2018).
- 630 15. WHO | Progress reports on HIV. (2020).
- 631 16. McLaren, P. J. et al. Fine-mapping classical HLA variation associated with durable host
- control of HIV-1 infection in African Americans. *Hum. Mol. Genet.* **21**, 4334–4347 (2012).

- 17. Taliun, D. et al. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program.
- 634 bioRxiv 563866 (2019) doi:10.1101/563866.
- 635 18. Okada, Y. et al. Deep whole-genome sequencing reveals recent selection signatures linked
- to evolution and disease risk of Japanese. *Nat. Commun.* **9**, 1631 (2018).
- 637 19. Mitt, M. et al. Improved imputation accuracy of rare and low-frequency variants using
- population-specific high-coverage WGS-based imputation reference panel. Eur. J. Hum.
- 639 *Genet.* **25**, 869–876 (2017).
- 640 20. Hirata, J. et al. Genetic and phenotypic landscape of the major histocompatibility complex
- region in the Japanese population. *Nat. Genet.* (2019) doi:10.1038/s41588-018-0336-0.
- 642 21. 1000 Genomes Project Consortium et al. A global reference for human genetic variation.
- 643 *Nature* **526**, 68–74 (2015).
- 644 22. Nelis, M. et al. Genetic structure of Europeans: a view from the north--east. PLoS One 4,
- 645 (2009).
- 646 23. Dilthey, A., Cox, C., Iqbal, Z., Nelson, M. R. & McVean, G. Improved genome inference in
- the MHC using a population reference graph. *Nature Genetics* vol. 47 682–688 (2015).
- 648 24. Dilthey, A. T. et al. High-Accuracy HLA Type Inference from Whole-Genome Sequencing
- Data Using Population Reference Graphs. *PLoS Comput. Biol.* **12**, e1005151 (2016).
- 650 25. Dilthey, A. T. et al. HLA*LA-HLA typing from linearly projected graph alignments.
- 651 Bioinformatics **35**, 4394–4396 (2019).
- 652 26. Browning, B. L. & Browning, S. R. A fast, powerful method for detecting identity by descent.
- 653 Am. J. Hum. Genet. 88, 173–182 (2011).
- 654 27. Hill, A. V. et al. Common west African HLA antigens are associated with protection from
- severe malaria. *Nature* **352**, 595–600 (1991).
- 656 28. Sanchez-Mazas, A. et al. The HLA-B landscape of Africa: Signatures of pathogen-driven

- 657 selection and molecular identification of candidate alleles to malaria protection. *Mol. Ecol.*
- 658 **26**, 6238–6252 (2017).
- 659 29. Maiers, M., Gragert, L. & Klitz, W. High-resolution HLA alleles and haplotypes in the United
- States population. *Hum. Immunol.* **68**, 779–788 (2007).
- 661 30. Gonzalez-Galarza, F. F. et al. Allele frequency net database (AFND) 2020 update:
- gold-standard data classification, open access genotype data and new query tools. *Nucleic*
- 663 Acids Res. 48, D783–D788 (2020).
- 664 31. Nothnagel, M., Fürst, R. & Rohde, K. Entropy as a measure for linkage disequilibrium over
- 665 multilocus haplotype blocks. *Hum. Hered.* **54**, 186–198 (2002).
- 666 32. Okada, Y. et al. Construction of a population-specific HLA imputation reference panel and
- its application to Graves' disease risk in Japanese. *Nat. Genet.* **47**, 798–802 (2015).
- 668 33. Okada, Y. eLD: entropy-based linkage disequilibrium index between multiallelic sites. Hum
- 669 Genome Var 5, 29 (2018).
- 670 34. Chikata, T. et al. Host-specific adaptation of HIV-1 subtype B in the Japanese population. J.
- 671 *Virol.* **88**, 4764–4775 (2014).
- 672 35. Nomura, E. et al. Mapping of a disease susceptibility locus in chromosome 6p in Japanese
- patients with ulcerative colitis. Genes Immun. 5, 477–483 (2004).
- 674 36. Price, P. et al. The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8,
- DR3) with multiple immunopathological diseases. *Immunol. Rev.* **167**, 257–274 (1999).
- 676 37. Horton, R. et al. Variation analysis and gene annotation of eight MHC haplotypes: the MHC
- Haplotype Project. *Immunogenetics* **60**, 1–18 (2008).
- 678 38. Graham, R. R. et al. Visualizing human leukocyte antigen class II risk haplotypes in human
- 679 systemic lupus erythematosus. *Am. J. Hum. Genet.* **71**, 543–553 (2002).
- 680 39. Miller, F. W. et al. Genome-wide association study identifies HLA 8.1 ancestral haplotype


- alleles as major genetic risk factors for myositis phenotypes. *Genes Immun.* **16**, 470–480
- 682 (2015).
- 40. Haapasalo, K. et al. The Psoriasis Risk Allele HLA-C*06:02 Shows Evidence of Association
- with Chronic or Recurrent Streptococcal Tonsillitis. *Infect. Immun.* **86**, (2018).
- 685 41. Kløverpris, H. N. et al. HIV control through a single nucleotide on the HLA-B locus. J. Virol.
- 686 **86**, 11493–11500 (2012).
- 42. Salter-Townshend, M. & Myers, S. Fine-Scale Inference of Ancestry Segments Without
- 688 Prior Knowledge of Admixing Groups. *Genetics* **212**, 869–889 (2019).
- 689 43. Zhou, Q., Zhao, L. & Guan, Y. Strong Selection at MHC in Mexicans since Admixture. PLoS
- 690 Genet. 12, e1005847 (2016).
- 691 44. Meyer, D., C Aguiar, V. R., Bitarello, B. D., C Brandt, D. Y. & Nunes, K. A genomic
- perspective on HLA evolution. *Immunogenetics* **70**, 5–27 (2018).
- 693 45. Norris, E. T. et al. Admixture-enabled selection for rapid adaptive evolution in the Americas.
- 694 *bioRxiv* 783845 (2019) doi:10.1101/783845.
- 695 46. Guan, Y. Detecting structure of haplotypes and local ancestry. *Genetics* **196**, 625–642
- 696 (2014).
- 697 47. Maples, B. K., Gravel, S., Kenny, E. E. & Bustamante, C. D. RFMix: a discriminative
- 698 modeling approach for rapid and robust local-ancestry inference. Am. J. Hum. Genet. 93,
- 699 278–288 (2013).
- 700 48. Jia, X. et al. Imputing amino acid polymorphisms in human leukocyte antigens. PLoS One
- 701 **8**, e64683 (2013).
- 702 49. Mellors, J. W. et al. Quantitation of HIV-1 RNA in plasma predicts outcome after
- ⁷⁰³ seroconversion. *Ann. Intern. Med.* **122**, 573–579 (1995).
- 704 50. Bartha, I. et al. Estimating the Respective Contributions of Human and Viral Genetic

- Variation to HIV Control. *PLoS Comput. Biol.* **13**, e1005339 (2017).
- 706 51. Blanco-Gelaz, M. A. et al. The amino acid at position 97 is involved in folding and surface
- 707 expression of HLA-B27. *Int. Immunol.* **18**, 211–220 (2006).
- 708 52. Stewart-Jones, G. B. E. et al. Structures of Three HIV-1 HLA-B*5703-Peptide Complexes
- and Identification of Related HLAs Potentially Associated with Long-Term Nonprogression.
- 710 The Journal of Immunology vol. 175 2459–2468 (2005).
- 711 53. Archbold, J. K. et al. Natural micropolymorphism in human leukocyte antigens provides a
- basis for genetic control of antigen recognition. *J. Exp. Med.* **206**, 209–219 (2009).
- 713 54. Gaiha, G. D. et al. Structural topology defines protective CD8+ T cell epitopes in the HIV
- 714 proteome. *Science* **364**, 480–484 (2019).
- 715 55. Macdonald, W. A. et al. A naturally selected dimorphism within the HLA-B44 supertype
- alters class I structure, peptide repertoire, and T cell recognition. *J. Exp. Med.* **198**,
- 717 679–691 (2003).
- 718 56. Kloverpris, H. N. et al. HLA-B*57 Micropolymorphism Shapes HLA Allele-Specific Epitope
- 719 Immunogenicity, Selection Pressure, and HIV Immune Control. *Journal of Virology* vol. 86
- 720 919–929 (2012).
- 721 57. Carrington, M. & Walker, B. D. Immunogenetics of spontaneous control of HIV. Annu. Rev.
- 722 *Med.* **63**, 131–145 (2012).
- 723 58. Khera, A. V. et al. Genome-wide polygenic scores for common diseases identify individuals
- with risk equivalent to monogenic mutations. *Nat. Genet.* **50**, 1219–1224 (2018).
- 725 59. Khera, A. V. et al. Polygenic Prediction of Weight and Obesity Trajectories from Birth to
- 726 Adulthood. *Cell* **177**, 587–596.e9 (2019).
- 727 60. Torkamani, A. & Topol, E. Polygenic Risk Scores Expand to Obesity. Cell vol. 177 518–520
- 728 (2019).


- 729 61. Martin, A. R. et al. Clinical use of current polygenic risk scores may exacerbate health
- 730 disparities. *Nat. Genet.* **51**, 584–591 (2019).
- 731 62. Van der Auwera, G. A. et al. From FastQ data to high confidence variant calls: the Genome
- Analysis Toolkit best practices pipeline. *Curr. Protoc. Bioinformatics* **43**, 11.10.1–33 (2013).
- 733 63. Julg, B. et al. Possession of HLA class II DRB1*1303 associates with reduced viral loads in
- 734 chronic HIV-1 clade C and B infection. *J. Infect. Dis.* **203**, 803–809 (2011).
- 735 64. Schäfer, C., Schmidt, A. H. & Sauter, J. Hapl-o-Mat: open-source software for HLA
- haplotype frequency estimation from ambiguous and heterogeneous data. *BMC*
- 737 Bioinformatics **18**, 284 (2017).
- 738 65. Alexander, D. H., Novembre, J. & Lange, K. Fast model-based estimation of ancestry in
- 739 unrelated individuals. *Genome Res.* **19**, 1655–1664 (2009).
- 740 66. Price, A. L. et al. Long-range LD can confound genome scans in admixed populations.
- 741 American journal of human genetics vol. 83 132–5; author reply 135–9 (2008).
- 742 67. Pasaniuc, B. et al. Analysis of Latino populations from GALA and MEC studies reveals
- 743 genomic loci with biased local ancestry estimation. *Bioinformatics* **29**, 1407–1415 (2013).
- 744 68. McLaren, P. J. et al. Association study of common genetic variants and HIV-1 acquisition in
- 745 6,300 infected cases and 7,200 controls. *PLoS Pathog.* **9**, e1003515 (2013).
- 746 69. Okada, Y. et al. Contribution of a Non-classical HLA Gene, HLA-DOA, to the Risk of
- 747 Rheumatoid Arthritis. *Am. J. Hum. Genet.* **99**, 366–374 (2016).

Figures

Figure 1. Global diversity of the MHC region. (a) Principal component analysis of the
pairwise IBD distance between 21,546 samples using MHC region markers. Allele diversity of
(b) HLA-B and (c) HLA-DQA1 among five continental populations (AA=Admixed African;
EUR=European; LAT=Latino; EAS=East Asian; SAS=South Asian). The top two most common
alleles within each population group are named, the remaining alleles are grouped as 'others'.
(a)







(c)





Figure 2. Pairwise LD and haplotype structure for six classical HLA genes in five 758 population groups. (a) shows the pairwise normalized entropy (ε) measuring the difference of the haplotype frequency distribution for linkage disequilibrium and linkage equilibrium among 759 five population groups. It takes values between 0 (no LD) to 1 (perfect LD). (b) shows the 760 761 haplotype structures of the eight classical HLA genes in each population. The tile in a bar represents an HLA allele, and its height corresponds to the frequencies of the HLA allele. The 762 gray lines connecting between two alleles represent HLA haplotypes. The width of these lines 763 corresponds to the frequencies of the haplotypes. The most frequent long-range HLA 764 haplotypes within each population is bolded and highlighted in a color described by the key at 765 the bottom. 766

767 **(a)**



(b)





Figure 3. The multi-ethnic HLA reference panel shows improvement in allele diversity and imputation accuracy. (a). The number of HLA alleles at the two-field resolution included in the multi-ethnic HLA reference panel (N = 21,546) compared to the European only Type 1 Diabetes Genetics Consortium⁴⁸ (T1DGC) panel (N = 5,225) as well as a subset of the multi-ethnic HLA panel down-sampled to the same size as T1DGC. (b). The correlation between imputed and typed dosages of classical *HLA* alleles using the multi-ethnic HLA reference panel at one-filed (red), two-field (blue) and G-group resolution (black) of the 955 1000 Genomes subjects. (c). The imputation accuracy for five classical HLA genes at one-field, two-field and G-group resolution. (d). The imputation accuracy at G-group resolution of the 1000 Genomes subjects stratified by four diverse ancestries when using three different imputation reference panels as described in (a).






Figure 4. Stepwise conditional analysis of the allele and amino acid positions of classical HLA genes to HIV-1 viral load. Each circle point represents the linear regression -log10(P_{binary}) for all classical HLA alleles. Each diamond point represents -log10($P_{omnibus}$) for the 782 tested amino acid positions in HLA (blue=HLA-A; yellow=HLA-C; red=HLA-B; lightblue=HLA-DRB1; green=HLA-DQA1; purple=HLA-DQB1, darkgreen=HLA-DPA1; lightgreen=HLA-DPB1). Association at amino acid positions with more than two alleles was calculated using a multi-degree-of-freedom omnibus test. The dashed blacked line represents the significance threshold of $P = 5 \times 10^{-8}$. Each panel shows the association plot in the process of stepwise conditional omnibus test. (a) One-field classical allele B*57 ($P = 9.84 \times 10^{-138}$) and (b) amino acid position 97 in HLA-B ($P_{omnibus} = 2.86 \times 10^{-184}$) showed the strongest association 789 signal. Results conditioned on position 97 in HLA-B showed a secondary signal at (c) classical allele B*81:0101:G ($P=4.53\times 10^{-23}$) and (d) position 67 in HLA-B ($P_{omnibus}=1.08\times 10^{-40}$). Results conditioned on position 97 and 67 in HLA-B showed the same classical allele (e) B*81:0101G ($P = 2.70 \times 10^{-23}$) and (f) third signal at position 156 in HLA-B ($P_{omnibus} = 1.92 \times 10^{-30}$). Results conditioned on position 97, 67 and 156 int HLA-B showed a 795 fourth signal at (g) HLA-A*31 ($P = 2.45 \times 10^{-8}$) and (h) position 77 in HLA-A (796 $P_{omnibus} = 5.35 \times 10^{-7}$) outside HLA-B.






Figure 5. Location and effect of three independently associated amino acid positions in **HLA-B.** (a) Allele frequency of six residues at position 97 in HLA-B among three populations. (b) Effect on spVL (i.e., change in log10 HIV-1 spVL per allele copy) of individual amino acid residues at position 97 in HLA-B. Results were calculated per allele using linear regression 800 models, including gender and principal components within each ancestry as covariates. (c) 801 HLA-B (PDB ID code 2bvp) proteins. Omnibus and stepwise conditional analysis identified three 802 independent amino acid positions (positions 97 (red), 67 (orange), and 156 (green) in HLA-B. 803 (d) Effect on spVL (i.e., change in log10 HIV-1 spVL per allele copy) of individual amino acid 804 residues at each position reported in this and previous work 10,16. Results were calculated per 805 allele using linear regression models. The x-axis shows the effect size and its standard errors in 806 the joint analysis, and the y-axis shows the effect size and its standard error in individual 807 populations (purple = Admixed American; blue = European and orange = Latino). (e) Variance of 808 spVL explained by the haplotypes formed by different amino acid positions. 809



Amino acid residues at position 97 in HLA-B



810 Tables

Table 1. Effect estimates for the haplotypes defined by the three independent amino
acids in HLA-B associated with HIV-1 viral load. Only haplotypes with >1% frequency in the
overall population are listed (Supplementary Table 15). Classical alleles of HLA-B are grouped
based on the amino acid residues presented at position 97, 67 and 156 in HLA-B. For each
haplotype, the multivariate effect is given as an effect size, taking the most frequent haplotype
(97R-67S-156L) as the reference (effect size = 0). Heterogeneity p-value (P(het)) of each
haplotype is calculated using a F-statistics with two degrees of freedom (Methods). Effect size
and its standard error in each population are listed only for haplotypes that show evidence of
heterogeneity (P-value < 0.05 /26, bolded). Unadjusted haplotype frequencies are given in each
population.

HLA-B a	mino acid at	t position	Effect size (standard error)					Unadjusted allele frequency				HLA-B allele
97	67	156	AA	EUR	LAT	Joint	P(het)	AA	EUR	LAT	Joint	
V	М	L				-0.921 (0.036)	0.031	0.056	0.049	0.059	0.051	B*57:01;B 57:03
N	С	L				-0.554 (0.041)	0.257	0.012	0.046	0.037	0.035	B*27:05
Т	s	L				-0.436 (0.041)	0.041	0.028	0.039	0.056	0.037	B*13:02;B 52:01
W	С	L				-0.397 (0.041)	0.581	0.03	0.039	0.054	0.037	B*14:01;B 14:02
s	s	L				-0.252 (0.066)	0.013	0.002	0.014	0.07	0.013	B*40:02
R	S	w				-0.177 (0.038)	0.618	0.009	0.062	0.028	0.044	15:10;B*18 16
Т	F	L				-0.125 (0.036)	0.001	0.03	0.059	0.073	0.051	B*51:01;B 78:01
R	М	L				-0.125 (0.045)	0.375	0.061	0.014	0.028	0.029	B*15:16;B 58:01
R	С	L				-0.078 (0.039)	0.055	0.042	0.039	0.06	0.041	15:16;B*3:
R	S	D	0.165 (0.056)	-0.07 (0.034)	-0.153 (0.173)	-0.019 (0.028)	0.002	0.075	0.108	0.084	0.097	44:02;B*4: 01
R	S	L				Reference	0.536	0.191	0.176	0.197	0.18	15:10;B*1 01;B*39:1
S	Y	D				0.015 (0.055)	0.884	0.059	NA	0.017	0.019	B*42:01;B 42:02
s	Y	R	-0.06 (0.055)	0.037 (0.033)	-0.002 (0.187)	0.022 (0.027)	0.007	0.08	0.124	0.07	0.108	B*07:02;B 07:05
S	F	D				0.041 (0.031)	0.218	0.034	0.095	0.042	0.074	B*08:01
R	F	L				0.045 (0.027)	0.73	0.182	0.095	0.113	0.122	B*35:01;B 53:01
w	М	L				0.098 (0.064)	0.268	0.046	NA	NA	0.014	B*58:02
Т	Y	L				0.176 (0.058)	0.207	0.005	0.021	NA	0.016	